

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Nestle Health Science US Holdings, Inc.</u> _____ (Last) (First) (Middle) 1812 NORTH MOORE STREET _____ (Street) ARLINGTON VA 22209 _____ (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 12/31/2018	3. Issuer Name and Ticker or Trading Symbol <u>Aimmune Therapeutics, Inc. [AIMT]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)	5. If Amendment, Date of Original Filed (Month/Day/Year) _____ 6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person <input checked="" type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	11,727,113 ⁽¹⁾	I	See Footnote ⁽²⁾

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			

1. Name and Address of Reporting Person* <u>Nestle Health Science US Holdings, Inc.</u> _____ (Last) (First) (Middle) 1812 NORTH MOORE STREET _____ (Street) ARLINGTON VA 22209 _____ (City) (State) (Zip)

1. Name and Address of Reporting Person* <u>Societe des Produits Nestle S.A.</u> _____ (Last) (First) (Middle) AVENUE NESTLE 55 _____ (Street) CH-1800, VEVEY V8 _____ (City) (State) (Zip)
--

1. Name and Address of Reporting Person* <u>NESTLE SA</u>
--

(Last)	(First)	(Middle)
AVENUE NESTLE 55		
(Street)		
CH-1800, VEVEY	V8	
(City)		
(State)	(Zip)	

1. Name and Address of Reporting Person*

[NIMCO US, Inc.](#)

(Last)	(First)	(Middle)
1812 NORTH MOORE STREET		
(Street)		
ARLINGTON	VA	22209
(City)		
(State)	(Zip)	

1. Name and Address of Reporting Person*

[Nestle US Holdco, Inc.](#)

(Last)	(First)	(Middle)
1812 NORTH MOORE STREET		
(Street)		
ARLINGTON	VA	22209
(City)		
(State)	(Zip)	

Explanation of Responses:

1. This Form 3 is being filed to reflect the additions of Nestle US Holdco, Inc. ("Nestle US Holdco") and Societe des Produits Nestle S.A. ("SPN") as Reporting Owners as a result of a corporate reorganization completed December 31, 2018.
2. Held by Nestle Health Science US Holdings, Inc. ("NHS"). Following the corporate reorganization, NHS is a wholly owned subsidiary of NIMCO US, Inc. ("NIMCO"). NIMCO, in turn, is a wholly-owned subsidiary of Nestle US Holdco, which is a wholly-owned subsidiary of SPN. The ultimate parent company of NHS, NIMCO, Nestle US Holdco and SPN is Nestle S.A. ("Nestle"). Following the corporate reorganization, each of these entities may be deemed to share voting and investment power with respect to all shares of Common Stock held by NHS. Each of NIMCO, Nestle US Holdco, SPN and Nestle disclaims beneficial ownership of such shares of Common Stock except to the extent of its pecuniary interest therein.

Remarks:

[NESTLE HEALTH
SCIENCE US
HOLDINGS, INC. By: 04/24/2020
Name: James Pepin, Title:
Director and President](#)

[NIMCO US, INC. By:
Name: Dan Nugent, Title: 04/24/2020
Chief Legal Officer and
General Counsel](#)

[NESTLE US HOLDCO,
INC. By: Name: Michael 04/24/2020
Prewitt, Title: Secretary.](#)

[SOCIETE DES
PRODUITS NESTLE S.A. 04/24/2020
By: Name: Claudio Kuoni,
Title: Vice President](#)

[NESTLE S.A. By: Name:
Gregory Behar, Title: 04/24/2020
Deputy Executive Vice
President](#)

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.